Biora Therapeutics, Inc.

Greetings, and welcome to Biura Therapeutics' first quarter 2024 financial results call. At this time, all participants are in listen-only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star then zero on your telephone keypad. As a reminder, this conference is being recorded. I will now turn the call over to Chuck Pedalla, Managing Director with LifeSci Advisors, Bayora's Investor Relations Fund. Please go ahead.

Thank you, Operator. Good afternoon and welcome to the Bayora Therapeutics First Quarter 2024 Corporate Update and Financial Results Conference Call. Joining me on the call are Adi Mohanty, Chief Executive Officer, and Eric Desbarbis, Chief Financial Officer. Before I turn the call over to Mr. Mahanty, I would like to remind you that today's call will include forward-looking statements within the meaning of the federal securities law, including but not limited to the types of statements identified as forward-looking in our quarterly report on Form 10Q that we filed or will file later today and our subsequent reports filed with the SEC, which are available on our website in the investor section. These forward-looking statements represent our views only as of the date of this call and involve substantial risks and uncertainties, including many that are beyond our control. Please note that the actual results could differ materially from those expressed in the forward-looking statement. For a further description of the risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, as well as risks related to our business, please see the company's periodic reports filed with the SEC. With that, I'll now turn the call over to Adi Mahadi, CEO of Bayora Therapeutics. Adi?

Thanks, Chuck, and thank you, everyone, for joining us.